World Orphan Drug Congress 2018

Strategy, advocacy and partnering for the orphan drug industry

6th–8th November 2018, Pre-Congress Workshops 6th November
Hotel Crowne Plaza, Barcelona, Spain


2018 Advisory Board


Wills Hughes-Wilson, Former Senior Vice President, Chief Patient Access Officer, Sobi

Wills Hughes-Wilson  
Head of Patient Access & Commercial Planning 
Mereo Biopharma

Professor Michael Linden, Former VP Gene Therapy & Head, GMI, Pfizer

Professor Michael Linden   
Former VP Gene Therapy & Head, GMI

Yann Le Cam, Chief Executive Officer, EURORDIS

Yann Le Cam  
Chief Executive Officer  

Dr Ségolène Aymé, Founder of Orphanet, Emeritus Research Director, INSERM

Dr Ségolène Aymé  
Founder of Orphanet, Emeritus Research Director

Dr Bruno Sepodes, Chair of COMP, EMA

Dr Bruno Sepodes   
Chair of COMP

Sheela Upadhyaya, Assoc. Director Highly Specialised Technologies, National Institute For Health and Care Excellence

Sheela Upadhyaya   
Assoc. Director Highly Specialised Technologies
National Institute For Health and Care Excellence

Alastair Kent, Director, Genetic Alliance UK

Alastair Kent   
Former Director
Genetic Alliance UK

Dr Carlo Incerti, SVP, Head of Global Medical Affairs, CMO, Genzyme, A Sanofi Company

Dr Carlo Incerti    
SVP, Head of Global Medical Affairs, CMO
Genzyme, A Sanofi Company

Dr Mathew Pletcher, Head of Rare Disease Discovery, Roche

Dr Mathew Pletcher  
Head of Rare Disease Discovery

Dr M Ken Kengatharan, Managing Director, Atheneos Capital

M Ken Kengatharan  
Managing Partner, Atheneos Ventures and CEO
Auxesia Orion

Dr Birgitte Volck, SVP, Head of R&D Rare Diseases, GSK

Dr Birgitte Volck  

SVP, Head of R&D Rare Diseases 

Dr Pedro Franco, Former Scientific Administrator, EMA

Dr Pedro Franco  

Former Scientific Administrator 

Rick Thompson, CEO, Findacure

Rick Thompson  

Dr Alexander Natz, Secretary General, EUCOPE

Dr Alexander Natz 
Secretary General

Anna Bucsics, Project Advisor, MoCA

Anna Bucsics 
Project Advisor

Josie Godfrey, Former Associate Director, NICE

Josie Godfrey 
Former Associate Director

Dr Diego Ardigo, Chair, IRDiRC Therapies Scientific Committee & R&D Rare Diseases Unit Head at Chiesi Group

Dr Diego Ardigo
Chair, IRDiRC Therapies Scientific Committee & R&D Rare Diseases Unit Head at Chiesi Group





What is World Orphan Drug Congress?


World Orphan Drug Congress is Europe's meeting place for the rare disease community. The Conference offers strategic keynote plenaries, themed tracks and dedicated networking sessions, you have the chance to really tailor the event to the needs of your day-to-day role.

Exhibitors have a unique opportunity to put their business products and services in front of potential buyers looking to source the latest technologies in the orphan drugs industry. Meet and listen to biotech start-ups and investors in our Pitch & Partner track where the most promising companies showcase their orphan drug technology and pipeline.

Enjoy discussions on: 

Cell & Gene Therapies

Genetic Testing

Gene Editing

Partnering & Investment 

Global Market Access

Expanded Access Programs

Real World Evidence

Global Patient Advocacy

Value based pricing & reimbursement

Epidemiology & forecasting

Orphan Drugs Policy

Gene Therapy Development 

Together with:

Supported by:







Generate new business

Get your brand, your message and your sales people in front of your customers.

The congress opens doors to fantastic opportunities to form lucrative partnerships and source new ground-breaking solutions.



World Orphan Drug Congress 2018  sponsorship prospectus

Meet key orphan drug & rare disease decision makers

Speakers from 2018 include:





Who Attends


AANORA Actelion Pharma Ltd Action Duchenne Addmedica Adelphi Values AGSD (UK) AirLiquide

AKU Society Alcimed Alexion Pharmaceuticals Allaysis LLC Alliance Life Sciences ALS Liga Belgi

Alstrom Syndrome U.K. AMICULUM Anticancer Fund AOP Orphan Pharmaceuticals AG

ArmaGen Technologies, Inc. Atacsia a Fi / Ataxia and Me Ataxia UK aTyr aTyr Pharma

BioBlast Pharma Ltd Biopontis Alliance Blackswan Foundation Brace Pharma Capital

Caligor Rx, Inc. Calypso Biotech SA  Capsugel Celgene Centogene AG

Charity Association Neurohereditary Diseases Chiesi Farmaceutici Spa Clear Pharma

Clinart MENA Clinerion Clinigen Global Access Programs Comradis Concenter BioPharma/Silkim Ltd.

Cote Orphan Coulter Partners   Covance UK CRF Health CureDuchenne Cures Within Reach

Cydan Development  Cytokinetics Daiichi Sankyo Europe GmbH Dipharma SA Diurnal Limited

Dravet Syndrome Foundation Durbin E.C.R.I.N. ECRIN-ERIC ELA Suisse

Emmaus Life Sciences, Inc Ergomed EspeRare Euromedica EuropaBio

European Huntington's Disease Network EURORDIS  Euticals Spa EvaluatePharma Ltd

Evidera F.Hoffmann-La Roche Ltd. Facio Therapies BV Federal Joint Committee

F Hoffmann-La Roche French Association Against Friedreich Ataxia Gaucher Disease Russia

Genesis Pharma Genetic Alliance U.K. Genkyotex Innovation Sas Genpharm Genzyme Europe BV

Gerson Lehrman Group Giddi Pharma GlaxoSmithKline  Greenovation Biotech GmbH

Grünenthal GmbH GSK Rare Diseases GW Pharmaceuticals   Haute Autorite De Sante

Horizon Pharma Inc I.M.S. Health Idis Managed Access Idis Pharma

Imagine - Institut des Maladies génétiques IMS Health INC Research Index Ventures INSERM

 Lysogene M3 Pharma S/A Mapi Consultancy Midas Pharma GmbH Minoryx Therapeutics

MPS Society N.O.R.D. National Institute for Health and Care Excellence

National Institutes of Biomedical Innovation, Health and Nutrition

National organisation for rare diseases of Serbia  NephCure Kidney International Niemann-Pick UK Novartis



Join leading companies already benefiting from sponsorship & exhibiting




Join us in Barcelona this November



Follow us on


Sign Up for Event Updates

Get Involved At World Orphan Drug Congress 2018


To Sponsor Or Exhibit


Andrew Mears
t/ +44 20 7092 1228


To Speak


Wing-Yun Cheung
t/ +44 20 7092 1172


To Register


Issa Mauthoor
t/ +44 20 7092 1257